Home > Healthcare > Medical Devices > Diagnostic Devices > U.S. Direct-to-Consumer Genetic Testing Market

U.S. Direct-to-Consumer Genetic Testing Market Share

Report ID: GMI4368
Published Date: Jan 2023
Report Format: PDF

Download Free Sample

U.S. Direct-to-Consumer Genetic Testing Market Share

U.S. Direct-to-Consumer (DTC) Genetic Testing Market Size

To get key market trends

Download Free Sample

Some leading U.S. DTC genetic testing market players include

Ancestry
Easy DNA
23andMe, Inc.
HomeDNA
Counsyl
Living DNA Ltd.
Pathway genomics

Many of these companies are focusing on product innovations to keep ahead of the competition. For example, in January 2022, 23andMe, a consumer genetics and research firm, received FDA approval for its DTC genetic test on a hereditary prostate cancer marker. This strategic move will help the company enhance its position in the market landscape.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The U.S. market for DTC genetic testing was valued at over USD 1.5 billion in 2022 and is anticipated to grow at over 11% CAGR from 2023 to 2032., driven by rising cases of genetic disorders in the country.

Predictive testing segment is slated to grow at over 13% CAGR from 2023 to 2032, fueled by increasing occurrences of inherited disorders.

SNP chips segment is anticipated to grow at over 11.5% CAGR from 2023 to 2032, fueled by the rising use of SNP chips to determine the genome sequence and improve the efficiency of the tests.

Some major U.S. direct-to-consumer genetic testing market contenders include MyHeritage, Blueprint Genetics Oy, Ambry Genetics, DNA Genotek Inc, and Dante Lab, among others.